Shuttle Pharmaceuticals Holdings (SHPH) Cash & Equivalents (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 76.44% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 76.44% YoY), while the FY2025 annual figure was $257955.0, down 86.57% from the prior year.
• Cash & Equivalents was $1.1 million for Q1 2026 at Shuttle Pharmaceuticals Holdings, up from $257955.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.1 million in Q3 2022 to a low of $156656.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $3.3 million across 5 years, with a median of $2.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 6191.01% in 2022, then tumbled 95.97% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $5.4 million in 2022, then tumbled by 46.65% to $2.9 million in 2023, then plunged by 33.49% to $1.9 million in 2024, then plunged by 86.57% to $257955.0 in 2025, then surged by 312.0% to $1.1 million in 2026.
• The last three Cash & Equivalents figures came in at $1.1 million (Q1 2026), $257955.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.